Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Allakos Inc. (ALLK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results SAN CARLOS, Calif., August 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events • Presented preclinical data at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023 highlighting lirentelimab and AK006 mechanisms of action and inhibitory activity on IgE and non-IgE activated mast cells. Key findings of the presentation included: o AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib. o Siglec-6 interacts with ..."
05/09/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports First Quarter 2023 Financial Results SAN CARLOS, Calif., May 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Recent Allakos Events • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis during the first quarter of 2023. • Continued enrollment of a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria during the first quarter of 2023. Upcom..."
03/06/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN CARLOS, Calif., March 6, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab and AK006. Recent Allakos Events • Initiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in the third quarter of 2022. • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patien..."
11/07/2022 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results SAN CARLOS, Calif., November 7, 2022 – Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events • Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. o Initiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in the third quarter of 2022. The Phase 2b CSU clinical trial follows positive results from an open-label Phase 2a clinical trial with intravenou..."
08/04/2022 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results SAN CARLOS, Calif., August 4, 2022 – Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2022. Recent Allakos Events • Submitted End-of-Phase 2 briefing package to FDA to discuss Phase 2 KRYPTOS data and development pathway of lirentelimab in patients with eosinophilic esophagitis . Meeting with FDA scheduled for third quarter of 2022. Upcoming Allakos Milestones • Report topline data from Phase 3 EoDyssey study of lirentelimab in patients with eosinophilic duodenitis in third quarter of 2022. • Hold End-of-Pha..."
03/01/2022 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results REDWOOD CITY, Calif., March 1, 2022 – Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Events • Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis in the fourth quarter of 2021. • Reported topline data from ENIGMA 2, a Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with eosinophilic gastritis/eosinophilic duodenitis in the fourth ..."
11/08/2021 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results REDWOOD CITY, Calif., November 8, 2021 – Allakos Inc. , a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021. Recent Accomplishments  Presented data at American College of Gastroenterology 2021 Annual Scientific Meeting from prospective study showing high prevalence rates of eosinophilic gastritis and/or eosinophilic duodenitis with systemic evaluation. Forty-five percent of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for EG/EoD. This data..."
05/10/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Allakos Reports First Quarter 2020 Financial Results",
"Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting"
02/25/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
Docs: "Allakos Reports Second Quarter 2019 Financial Results"
05/08/2019 8-K Quarterly results
Docs: "Allakos Reports First Quarter 2019 Financial Results"
03/14/2019 8-K Quarterly results
Docs: "Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights"
08/29/2018 8-K Quarterly results
Docs: "Allakos Announces Second Quarter 2018 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy